Results of different studies that evaluated the effect of CCAAT Enhancer Binding Protein Alpha (CEBPA) mutations in clinical outcomes of pediatric acute myeloid leukemia (AML) patients. This evidence concerns the gene CEBPA and acute myeloid leukemia.